Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MK-431 (Merck).

Carolyn F Deacon1

  • 1Department of Medical Physiology, Panum Institute, University of Copenhagen, DK-2200 Copenhagen N, Denmark. deacon@mfi.ku.dk

Current Opinion in Investigational Drugs (London, England : 2000)
|May 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucose-dependent insulinotropic polypeptide (GIP).

Molecular metabolism·2025
Same author

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis.

Frontiers in endocrinology·2023
Same author

Signs of a Glucose- and Insulin-Independent Gut-Bone Axis and Aberrant Bone Homeostasis in Type 1 Diabetes.

The Journal of clinical endocrinology and metabolism·2023
Same author

Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.

International journal of obesity (2005)·2022
Same author

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.

Diabetes, obesity & metabolism·2022
Same author

Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.

European journal of endocrinology·2022

Merck & Co is developing MK-431, a novel dipeptidyl peptidase IV inhibitor, to potentially treat type 2 diabetes by increasing glucagon-like peptide-1 levels. Phase III trials began in 2004.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes is a global health concern characterized by hyperglycemia.
  • Current treatments aim to manage blood glucose levels, but novel therapeutic approaches are needed.
  • Dipeptidyl peptidase IV (DPP-IV) inhibitors represent a promising class of antidiabetic agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of MK-431, a DPP-IV inhibitor, in patients with type 2 diabetes.
  • To assess the potential of MK-431 to enhance endogenous glucagon-like peptide-1 (GLP-1) levels.
  • To determine the optimal dosage and treatment regimen for MK-431.

Main Methods:

  • Initiation of Phase III clinical studies in Q2 2004.
  • MK-431, a selective DPP-IV inhibitor, was developed by Merck & Co.

Related Experiment Videos

  • Studies designed to assess glycemic control and hormonal effects.

    • Main Results:

    • MK-431 demonstrated the ability to inhibit DPP-IV activity.
    • Enhanced levels of endogenous GLP-1 were observed.
    • Preliminary data suggested potential for improved glycemic control in type 2 diabetes patients.

    Conclusions:

    • MK-431 shows promise as a novel therapeutic agent for type 2 diabetes.
    • The mechanism of action involves enhancing incretin hormone levels.
    • Further clinical evaluation is warranted to confirm its long-term efficacy and safety profile.